Capital Fund Management S.A. Acquires 17,673 Shares of Exelixis, Inc. $EXEL

Capital Fund Management S.A. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 6.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 283,639 shares of the biotechnology company’s stock after buying an additional 17,673 shares during the period. Capital Fund Management S.A. owned 0.11% of Exelixis worth $12,501,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. raised its position in shares of Exelixis by 2.2% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock valued at $287,794,000 after acquiring an additional 164,134 shares during the last quarter. Geode Capital Management LLC increased its holdings in Exelixis by 0.4% in the second quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after purchasing an additional 28,289 shares during the last quarter. AQR Capital Management LLC lifted its stake in Exelixis by 73.8% in the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock valued at $250,869,000 after buying an additional 2,926,884 shares during the period. Invesco Ltd. lifted its stake in Exelixis by 40.2% in the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock valued at $205,725,000 after buying an additional 1,596,948 shares during the period. Finally, Nuveen LLC bought a new position in Exelixis during the first quarter worth about $123,310,000. 85.27% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EXEL. Stifel Nicolaus set a $43.00 price target on Exelixis in a research note on Wednesday, November 5th. Cowen reiterated a “buy” rating on shares of Exelixis in a report on Wednesday, November 5th. Royal Bank Of Canada reissued a “sector perform” rating and set a $45.00 price target on shares of Exelixis in a research report on Tuesday, October 21st. Oppenheimer restated a “market perform” rating and issued a $36.00 price objective on shares of Exelixis in a research report on Wednesday, November 5th. Finally, Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average target price of $45.45.

Insider Activity

In related news, EVP Dana Aftab sold 48,383 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the transaction, the executive vice president directly owned 664,778 shares of the company’s stock, valued at approximately $28,253,065. The trade was a 6.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stelios Papadopoulos sold 100,000 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the transaction, the director directly owned 1,189,228 shares in the company, valued at $51,790,879.40. The trade was a 7.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 245,235 shares of company stock valued at $10,490,600 over the last three months. Corporate insiders own 2.82% of the company’s stock.

Exelixis Stock Performance

NASDAQ:EXEL opened at $44.12 on Friday. Exelixis, Inc. has a 52-week low of $31.90 and a 52-week high of $49.62. The company has a market cap of $11.83 billion, a P/E ratio of 21.21, a P/E/G ratio of 0.79 and a beta of 0.32. The stock’s 50-day simple moving average is $40.24 and its 200 day simple moving average is $40.87.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.